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Abstract
Background:  Between 1992 and 2001 the UK general practice incidence of post-herpetic
neuralgia and trigeminal neuralgia declined, whilst the incidence of painful diabetic neuropathy
increased. The most common first line treatments were compound analgesics. As therapeutic
options have subsequently changed, this study presents updated data on incidence and prescribing
patterns in neuropathic pain.
Methods: A descriptive analysis of the epidemiology and prescription treatment at diagnosis of
incident post-herpetic neuralgia (n = 1,923); trigeminal neuralgia (1,862); phantom limb pain (57)
and painful diabetic neuropathy (1,444) using computerised UK general practice records (THIN):
May 2002 to July 2005.
Results: Primary care incidences per 100,000 person years observation of 28 (95% confidence
interval (CI) 27–30) for post-herpetic neuralgia, 27 (95%CI 26–29) for trigeminal neuralgia, 0.8
(95%CI 0.6–1.1) for phantom limb pain and 21 (95%CI 20–22) for painful diabetic neuropathy are
reported. The most common initial treatments were tricyclic antidepressants (post-herpetic
neuralgia) or antiepileptics (trigeminal neuralgia and painful diabetic neuropathy) and opioid
analgesics (phantom limb pain). The mean number of changes before a stable drug regimen was 1.2
to 1.5 for trigeminal neuralgia, painful diabetic neuropathy and post-herpetic neuralgia, and 2.4 for
phantom limb pain.
Conclusion: The incidence of phantom limb pain and post-herpetic neuralgia are decreasing whilst
painful diabetic neuropathy plateaued and trigeminal neuralgia remained constant. Despite more
frequent use of antidepressants and antiepileptics for first line treatment, as opposed to
conventional non-opioid analgesics, changes to therapy are common before a stable regimen is
reached.
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Background
A fifth of adults in Europe have moderate or severe
chronic pain but, although only 2% are managed by a spe-
cialist [1], most published data on the epidemiology and
treatment of pain conditions come from secondary care
sources [2-6]. The prevalence of pain of predominantly
neuropathic origin has been reported as 8% in a UK pri-
mary care survey [7]. One UK General Practice Research
Database study investigated the epidemiology and treat-
ment of four neuropathic pain syndromes; post-herpetic
neuralgia, trigeminal neuralgia, phantom limb pain and
painful diabetic neuropathy [8]. Data from 1992 to 2002
showed trends in incidence of disease, with painful dia-
betic neuropathy and trigeminal neuralgia increasing over
the ten years while post-herpetic neuralgia and phantom
limb pain decreased. Co-proxamol, carbamazepine,
amitriptyline, codeine plus paracetamol and co-dydramol
were the five most common medications included in ini-
tial treatments across all four conditions. Within the more
commonly prescribed therapies, those patients who
received an antiepileptic or an antidepressant at the time
of diagnosis were shown to be less likely to switch ther-
apy.
It was anticipated that prescribing patterns for the neuro-
pathic pain conditions would have changed recently with
negative publicity concerning co-proxamol [9], increased
use of newer therapies such as gabapentin, and changes to
prescribing guidance [10]. Continuing changes in inci-
dence rates may have an impact on workload. The objec-
tive of this study was to investigate current prescribing
patterns and to update the incidence estimates for neuro-
pathic pain syndromes.
Methods
The study was an observational, descriptive study of
patients with an incident diagnosis of one of four neuro-
pathic pain syndromes. All data were obtained from the
Health Information Network database (THIN), which is
an observational database containing primary care
records from throughout the UK. Details of demograph-
ics, primary care diagnoses and prescription treatment are
routinely recorded against date in individual patient
records. Information on referrals, secondary care diag-
noses and deaths are also captured because of the struc-
ture of the UK National Health Service (NHS). Within the
NHS, the general population are registered with one Gen-
eral Practitioner (GP) and remain on that GP's list whilst
being treated by hospital specialists or hospitalized. Major
events from before computerization are added retrospec-
tively. Medical events are recorded using the Read Coding
system [11].
Study Populations
The study population comprised all patients who were
permanently registered at one of the practices contribut-
ing to THIN at any time in the study period, May 2002 to
July 2005; that is over 2.9 million patients from 295 prac-
tices, 51% female and 20% over 60 years of age. The files
of all patients in the study population were searched for a
record of any of the four forms of neuropathic pain stud-
ied [see Additional file 1]. The index date was the date of
the first record of the neuropathic pain or neuropathy.
Patients could be in more than one category. A post-her-
petic neuralgia record was a specific term for post-herpetic
neuralgia or an acute herpes zoster term plus either neu-
ropathy, or neuropathic pain, 3–6 months after the first
acute herpes zoster entry. A trigeminal neuralgia record
had a specific term for this diagnosis. Phantom limb pain
was defined as a specific term or a term for amputation
plus either a neuropathy or neuropathic pain record 3–24
months after the first amputation code. Patients were
included in the painful diabetic neuropathy cohort if their
record contained a specific term; a term for diabetic neu-
ropathy with a prescription for a treatment for pain cur-
rent at the date of diagnosis; a record of diabetes and a
general term for neuropathic pain or record of diabetes
and both neuralgia and a treatment for pain current on
the date of the neuralgia code. A neuropathic pain treat-
ment was defined as an analgesic (excluding low dose
aspirin), an anaesthetic (oral or intravenous), an antiepi-
leptic with no history of epilepsy, or an antidepressant. A
sensitivity analysis was included in the study of painful
diabetic neuropathy to assess the impact of removing
patients with a prescription for a treatment for pain, cur-
rent at the date of diagnosis, but not initiated on this date.
This group may have included patients with non-painful
diabetic neuropathy who were being treated for depres-
sion or other painful conditions.
The person years observation and incidence per person
years observation were estimated for each form of neuro-
pathic pain. Those with a first record of their neuropathic
pain dated during their period of observation counted as
incident cases and formed the neuropathic pain cohorts.
A period of observation was assigned for each patient. The
start of observation was the later of May 2002, or one year
after the date that either the practice started using the
Vision Computer System or the patient registered at that
practice. The year was added to allow time for the record-
ing of prevalent events. The end of observation was the
earliest of the following: death, transfer-out of the prac-
tice, the final data collection or the end of July 2005. Inci-
dence rates were age adjusted by direct standardisation to
the UK figures for 2005 [12].BMC Family Practice 2008, 9:26 http://www.biomedcentral.com/1471-2296/9/26
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Treatment Patterns
The computerised treatment records of each patient in the
incident neuropathic pain cohorts were searched for an
initial treatment, defined as any treatment for neuropathic
pain started within 28 days of the first record of the diag-
nosis. If more than one therapy was prescribed in this
period then that nearest to the first record was the initial
treatment. When more than one item was prescribed on
the same day, the initial treatment was considered to be
the combination of these therapies. For the four study
conditions, the number of patients with each initial drug
regimen (drug and daily dose), therapeutic class, and
number of therapies per patient were counted. Therapeu-
tic class was based on the British National Formulary [13].
Daily doses which could not be interpreted from the com-
puter record were grouped, as were those that were inter-
preted but were not specific (for example: '2–3, 3–4 times
a day', 'as directed' or 'as required'). The latter group was
labelled 'dose not specified'. When a prescription
described a dose titration, then the final dose was
included. The duration was calculated for each initial
treatment. A therapy was considered to have stopped
when no additional prescription was issued within 56
days, a concomitant drug was introduced or, for combina-
tion therapies, one therapy was stopped. When the dura-
tion could not be calculated from details on a
prescription, it was assumed to last 28 days.
To understand changes in treatment a sub-group of
patients who received an initial treatment and who could
be followed for at least one further year were identified.
Prescription records during the year were searched for any
changes in neuropathic pain treatment. Changes to ther-
apy included each switch, new treatment, discontinuation
or addition of a concomitant drug. A switch was defined
as prescriptions for more than one drug, where the pre-
scription for the first drug was dated before that of the sec-
ond, with less than 56 days between these prescriptions,
and no subsequent treatment for the first drug in the 56
days after the prescription for the second drug. A new
treatment was defined as prescriptions for more than one
drug, where one prescription was dated after the other,
with between 56 days and 6 months between the prescrip-
tions and no subsequent treatment for the first drug in the
56 days after the second prescription. Concomitant ther-
apy was defined as prescriptions for more than one treat-
ment where the date of the second prescription was on or
after the starting treatment date but on or before the date
of the last prescription in a treatment episode (one or
more prescriptions separated by less than 56 days). A dis-
continuation was defined as no further prescriptions for
that drug. Stable therapy was defined as more than two
prescriptions for the same drug or drugs (ignoring daily
dose) with less than 56 days between them, and without
a break of more than 6 months with no neuropathic pain
treatment. The number of patients who reached a stable
therapy regimen within the year was counted.
Ethics approval was given by London MREC, reference
number 05/MRE02/77.
Results
Incident cases of one or more of the four neuropathic pain
conditions were identified for 5,445 patients during the
period of observation. There were 1,923 incident cases of
post-herpetic neuralgia, incidence 28.2 per 100,000 per-
son years (95% CI 27.0, 29.5) and 1,862 cases of trigemi-
nal neuralgia, incidence 27.3 (95% CI 26.1–28.6) and 57
of phantom limb pain, incidence 0.8 (95% CI 0.6–1.1).
The incidence of painful diabetic neuropathy was 27.2
(95% CI 26.0–28.4), n = 1,867, and 26.1 per 100,000 per-
son years when the stricter definition was used excluding
those whose pain treatment did not start at the time of the
first diagnosis record. The age standardised incidence rates
(to UK 2005) were 27.3 per 100,000 person years for post
herpetic neuralgia, 26.7 for trigeminal neuralgia, 0.8 for
phantom limb pain and 26.7 for painful diabetic neurop-
athy.
A treatment for neuropathic pain was initiated at the time
of the first diagnosis record for between 49.4% and 73.5%
of patients with a neuropathic pain condition (Table 1).
The mean duration of this treatment varied between 50
days for post-herpetic neuralgia and 90 days for trigemi-
nal neuralgia. The tricyclic antidepressant amitriptyline
was the most frequently prescribed treatment for post-her-
petic neuralgia, phantom limb pain and painful diabetic
neuropathy, and the second most commonly prescribed
in trigeminal neuralgia. Carbamazepine an antiepileptic
was the most common item on the initial prescription for
those diagnosed with trigeminal neuralgia (Table 1). The
majority of patients were prescribed one treatment when
therapy was initiated so the majority of patients received
one therapeutic class of drug (Table 2). At the time of the
first record, 46.8% of patients with trigeminal neuralgia
started treatment with carbamazepine, however 52.7%
were being treated with this drug. Antidepressants and
antiepileptics were prescribed in an initial treatment to
the majority of patients: 75% of patients with trigeminal
neuralgia, 63% with painful diabetic neuropathy or phan-
tom limb pain, and 57% of those with post-herpetic neu-
ralgia (Table 3). Between 55 and 68% of the treated
cohorts had at least one year of data after this initial treat-
ment. For those who reached stable therapy during this
period the median number of preceding changes was two
for trigeminal neuralgia and painful diabetic neuropathy
and three for post-herpetic neuralgia and phantom limb
pain (Table 3). There was great variation in initial treat-
ments with no treatment – dose combination given to
more than nine percent of patients (Table 4).BMC Family Practice 2008, 9:26 http://www.biomedcentral.com/1471-2296/9/26
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Within those patients in the phantom limb pain cohort,
and followed for at least one year, no initial treatment
(drug and daily dose combination) had been prescribed
to ten or more patients. For post-herpetic neuralgia and
painful diabetic neuropathy the most common drug and
dose combinations were amitriptyline 10 or 25 milli-
grams per day and 10 milligrams 'dose not specified'. Car-
bamazepine 200 milligrams per day was the most
common treatment for trigeminal neuralgia, followed by
amitriptyline 10 milligrams per day and 10 milligrams
'dose not specified'.
Discussion
This large study aimed to provide updated incidence rates
and prescribing practices for four neuropathic pain condi-
tions as seen by UK general practitioners rather than in
secondary care clinics. The population was similar to that
of the UK in terms of age and sex, 51% were female as in
the UK 2001 census data, while there were slightly fewer
elderly patients, 20% over 60 years of age compared to
21% [14].
The incidence rate of 28.2 per 100,000 patient years for
post-herpetic neuralgia is in-line with other published
findings [15,16] which give rates of 34 and 49 per
100,000 person years one month after acute herpes zoster.
When compared to data from a similar general practice
study, the incidence had decreased since 1998–2001, age-
adjusted incidence of 56.8 per 100,000 population com-
pared to 27.3 in 2002–2005 [8]. This may relate to the
definition of PHN which included a GP diagnosis of post-
herpetic neuralgia. A GP's perception of post herpetic neu-
ralgia may include acute or sub-acute zoster pain. In addi-
tion to inflating the true incidence rate, if perceptions
change with time and possibly education, this could
explain the declining rates. Alternatively, treatment of
acute herpes zoster with antiviral agents has been reported
to reduce both the risk of developing post-herpetic neural-
gia and the overall the duration of pain [17]. No UK data
were available on the use of antivirals in herpes zoster, but
information from the Netherlands suggest that, while they
are used in a minority of patients (22.5%), treatment is
more common in those at higher risk of complications
[18]. Without intervention the rising age of the UK popu-
lation might be expected to result in higher rates of post-
herpetic neuralgia as age is a risk factor for both acute her-
pes zoster and post-herpetic neuralgia in acute herpes
zoster [19].
Our finding of an incidence of trigeminal neuralgia of 27
per 100,000 person years is consistent with the previous
database study, however these rates are considerably
higher than those previously published (2.1 to 4.7 per
100,000 patient years and 8 per persons per annum [20-
22]). This further supports the view that primary care phy-
sicians use a wide definition when they diagnose trigemi-
nal neuralgia. The incidence of phantom limb pain of 0.8
per 100,000 person years is slightly less than the 1998–
2001 rate of 0.9 [8] (age-adjusted rates of 0.8 per 100,000
person years and 1.3 in 1998–2001) as might be expected
Table 1: Initial treatmentsa by pain condition
Post Herpetic Neuralgia Trigeminal Neuralgia Phantom Limb Pain Painful Diabetic 
Neuropathy
Number with an initial 
treatment (% total with 
condition)
1,414 (73.5) 1,164 (62.5) 40 (70.2) 922 (49.4)
Duration of initial treatmentb 
in days mean (± SD)
50.5 (126.3) 90.0 (168.6) 73.1 (192.9) 77.1 (141.2)
Items prescribed on initial prescription as % of those treated
1 item 56.2 72.6 52.5 63.7
2 items 24.6 15.9 40.0 24.2
3 or more items 19.2 11.5 7.5 12.1
Five most common medications included in initial treatments, n (% treated)
1 Amitriptyline 
hydrochloride 704 (49.8)
Carbamazepine 545 (46.8) Amitriptyline 
hydrochloride 12 (30.0)
Amitriptyline 
hydrochloride 375 (40.7)
2 Codeine phosphate 
+paracetamol 248 (17.5)
Amitriptyline 
hydrochloride 304 (26.1)
Gabapentin 9 (22.5) Gabapentin 154 (16.7)
3 Capsaicin 149 (10.5) Codeine phosphate 
+paracetamol 131 (11.3)
Paracetamol 6 (15.0) Codeine phosphate+ 
paracetamol 112 (12.1)
4 Co-dydramol 126 (8.9) Gabapentin 99 (8.5) Codeine phosphate+ 
paracetamol 5 (12.5)
Paracetamol 97 (10.5)
5 Carbamazepine 118 (8.3) Co-proxamol 59 (5.1) Carbamazepine 3 (7.5) Co-dydramol 54 (5.9)
aStarted within 28 days of the first record of the disease. bDuration of initial treatment in days, ignoring titration of dose. SD, standard deviationsBMC Family Practice 2008, 9:26 http://www.biomedcentral.com/1471-2296/9/26
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given the lower rate of limb amputations [23]. No other
community based incidence rates were found for phan-
tom limb pain.
Incidence rates for painful diabetic neuropathy, from
both this and the previous UK general practice study are
considered to be maximum incidences. The data source
did not allow separation of patients with non-painful dia-
betic neuropathy who had a treatment for depression or
other pain initiated at the same time as the neuropathy
was first recorded from those treated for painful diabetic
neuropathy. Although the crude incidence of painful dia-
betic neuropathy increased, age-adjusted rates (taking
into account the new dataset) were the same for the 1998–
2001 and 2002–2005 data.
Neuropathic pain treatment
A treatment was initiated at the time of diagnosis for
between 40% and 74% of patients in the neuropathic
cohorts. Other patients may have been established on a
treatment before a firm diagnosis was made, particularly
as definitions for both phantom limb pain and post-her-
petic neuralgia include a delay between the precipitating
event and diagnosis. The prescribing of antidepressants
and antiepileptics is in-line with UK guidelines for neuro-
pathic pain treatment [13,24], although amitriptyline is
not included in these recommendations for the first line
treatment of trigeminal neuralgia. Amitriptyline is the tri-
cyclic antidepressant of choice in all cohorts despite evi-
dence that imipramine and nortriptyline are also effective
[24]. Prescribing paracetamol alone, or in combination
with codeine, is recommended for post-herpetic neuralgia
patients with mild to moderate pain [10]. Our finding
that combination therapy was more common than para-
cetamol alone could, in part, be due to the availability of
over the counter paracetamol.
When compared to prescribing in the previous, similar
UK primary care study [8] the 2002 to 2005 data show an
increase in the use of antidepressants and antiepileptics
while prescribing of conventional non-opioid analgesics
declined. Across all four conditions there was a two to
four fold increase in use in amitriptyline between the Jan-
uary 1992 to April 2002 and May 2002 to July 2005
cohorts (1992-April 2002 data:12%, 6%, 8% and 24% for
post-herpetic neuralgia, trigeminal neuralgia, phantom
limb pain and painful diabetic neuropathy respectively).
Gabapentin is now one of the five most common initial
treatments in three of the conditions, the exception being
post-herpetic neuralgia, and has replaced carbamazepine
Table 2: Initial treatments by condition and combination of therapeutic class (percentage of treated patients)
Post-herpetic 
neuralgia
Trigeminal 
neuralgia
Phantom limb 
pain
Painful diabetic 
neuropathy
N (%) N (%) N (%) N (%)
Opioid analgesics alone 84 (5.9) 45 (3.9) 7 (17.5) 47 (5.1)
Opioid analgesics + Antidepressants (tricyclic) 41 (2.9) 12 (1.0) 2 (5.0) 21 (2.3)
Opioid analgesics + Antidepressants (other) 2 (0.1) 1 (0.1) 0 4 (0.4)
Opioid analgesics + Antiepileptics 13 (0.9) 22 (1.9) 0 8 (0.9)
Opioid analgesics + Non-opioid analgesics 168 (11.9) 94 (8.1) 5 (12.5) 97 (10.5)
Opioid analgesics + Rubefacients 6 (0.4) 1 (0.1) 0 2 (0.2)
Antidepressants (tricyclic) alone 445 (31.5) 225 (19.3) 8 (20.0) 281 (30.5)
Antidepressants (tricyclic) + Antidepressants (other) 2 (0.1) 1 (0.1) 0 5 (0.5)
Antidepressants (tricyclic) + Antiepileptics 7 (0.5) 12 (1.0) 0 14 (1.5)
Antidepressants (tricyclic) + Non-opioid analgesics 68 (4.8) 21 (1.8) 1 (2.5) 35 (3.8)
Antidepressants (tricyclic) + Rubefacients 17 (1.2) 2 (0.2) 0 2 (0.2)
Antidepressants (tricyclic) + Local anaesthetics 2 (0.1) 0 0 0
Antidepressants (other) alone 7 (0.5) 7 (0.6) 2 (5.0) 23 (2.5)
Antidepressants (other) + Antiepileptics 2 (0.1) 10 (0.9) 1 (2.5) 8 (0.9)
Antidepressants (other) + Non-opioid analgesics 4 (0.3) 1 (0.1) 1 (2.5) 5 (0.5)
Antidepressants (other) + Rubefacients 3 (0.2) 0 0 0
Antiepileptics alone 158 (11.2) 543 (46.7) 7 (17.5) 165 (17.9)
Antiepileptics + Non-opioid analgesics 15 (1.1) 13 (1.1) 3 (7.5) 5 (0.5)
Antiepileptics + Rubefacients 8 (0.6) 2 (0.2) 0 5 (0.5)
Antiepileptics + Local anaesthetics 2 (0.1) 1 (0.1) 0 0
Non-opioid analgesics alone 70 (5.0) 43 (3.7) 1 (2.5) 72 (7.8)
Non-opioid analgesics + Rubefacients 7 (0.5) 0 0 2 (0.2)
Rubefacients alone 78 (5.5) 12 (1.0) 0 37 (4.0)
Local anaesthetics alone 2 (0.1) 4 (0.3) 0 8 (0.9)
1 therapeutic category 844 (59.7) 879 (75.5) 25 (62.5) 633 (68.7)
2 therapeutic categories 367 (26.0) 193 (16.6) 13 (32.5) 213 (23.1)
3 or more therapeutic categories 203 (14.4) 92 (7.9) 2 (5.0) 76 (8.2)BMC Family Practice 2008, 9:26 http://www.biomedcentral.com/1471-2296/9/26
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as the most commonly prescribed antiepileptic for phan-
tom limb pain and painful diabetic neuropathy. Gabap-
entin was not licensed for neuropathic pain until 2000
and so was not a frequently prescribed treatment for any
condition in the earlier analysis. Carbamazepine use
increased only in the treatment of post-herpetic neuralgia.
While the negative press reports concerning the associa-
tion of co-proxamol and fatal overdose may have
accounted for some of the change, the decreased use of all
non-opioid analgesics is probably due to increased evi-
dence and acceptance of efficacy of other agents [25-29].
The withdrawal of co-proxamol was not announced until
February 2005 so will have had little effect on this study.
Another change was the inclusion of the rubefacient cap-
Table 3: Number of changesa from initialb to stablec therapy by condition and therapeutic class included in the prescription
Number of patients Changes to stable therapy in 1 year
Initial Treatment Includes: Treated 
(% all treatedd)
Followed >1 year 
(% treated)
Stable in 1 year 
(%followed)
Median Range
Post-herpetic neuralgia:
Total 1414 828 (58.6) 232 (28.0) 3 0–20
Antiepileptics 248 (17.5) 153 (61.7) 46 (30.1) 3 1–20
Antidepressants (tricyclics) 728 (51.5) 422 (58.0) 104 (24.6) 2 0–11
Antidepressants (other) 39 (2.8) 26 (66.7) 10 (38.5) 4 2–8
Non-opioid analgesics 529 (37.4) 310 (58.6) 103 (33.2) 3 0–18
Opioid analgesics 504 (35.6) 277 (55.0) 92 (33.2) 3 0–18
Rubefacients/other topical 
antirheumatics
150 (10.6) 91 (60.7) 29 (31.9) 2 1–8
Local anaesthetics 8 (0.6) 4 (50.0) 2 (50.0) 3 1–4
Trigeminal neuralgia:
Total 1164 762 (65.5) 168 (22.0) 2 0–17
Antiepileptics 653 (56.1) 433 (66.3) 91 (21.0) 2 0–17
Antidepressants (tricyclics) 318 (27.3) 205 (64.5) 43 (21.0) 2 1–12
Antidepressants (other) 29 (2.5) 16 (55.2) 4 (25.0) 2 1–5
Non-opioid analgesics 258 (22.2) 169 (65.5) 40 (23.7) 2 0–17
Opioid analgesics 260 (22.3) 165 (63.5) 45 (27.3) 3 1–17
Rubefacients/other topical 
antirheumatics
24 (2.1) 14 (58.3) 4 (28.6) 6 2–12
Local anaesthetics 5 (0.4) 3 (60.0) 1 (33.3) 4 4-4
Phantom limb pain:
Total 40 27 (67.5) 13 (48.1) 3 1–53
Antiepileptics 11 (27.5) 8 (72.7) 2 (25.0) 3 2–3
Antidepressants (tricyclics) 13 (32.5) 8 (61.5) 5 (62.5) 3 1–36
Antidepressants (other) 4 (10.0) 3 (75.0) 3 (100.0) 1 1–53
Non-opioid analgesics 13 (32.5) 8 (61.5) 3 (37.5) 1 1–3
Opioid analgesics 16 (40.0) 9 (56.3) 5 (55.6) 3 1–5
Rubefacients/other topical 
antirheumatics
0- ---
Local anaesthetics 0 - - - -
Painful diabetic neuropathy:
Total 922 508 (55.1) 161 (31.7) 2 0–31
Antiepileptics 237 (25.7) 107 (45.1) 41 (38.3) 2 0–16
Antidepressants (tricyclics) 404 (43.8) 233 (57.7) 73 (31.3) 2 0–12
Antidepressants (other) 59 (6.4) 30 (50.8) 12 (40.0) 4 1–8
Non-opioid analgesics 283 (30.7) 171 (60.4) 48 (28.1) 2 0–31
Opioid analgesics 249 (27.0) 137 (55.0) 54 (39.4) 2 0–31
Rubefacients/other topical 
antirheumatics
54 (5.9) 34 (63.0) 14 (41.2) 2 1–8
Local anaesthetics 9 (1.0) 8 (88.9) 3 (37.5) 1 1–7
aTreatment changes comprised each switch, discontinuation, new treatment or addition of a concomitant treatment, but not a change in dose. 
bStarted within 28 days of the first record of the disease. cMore than two prescriptions for the same treatment with less than 56 days between 
them. d Some patients had more than 1 therapeutic class in the initial therapy, percentages add to >100.BMC Family Practice 2008, 9:26 http://www.biomedcentral.com/1471-2296/9/26
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saicin in the top five most frequently prescribed items for
post-herpetic neuralgia, possibly because it was not
licensed for neuropathic pain for all of the earlier study
period and was not included in previous management rec-
ommendations.
The study used the most up to date records available. This
allowed us to provide current incidence figures, but meant
that we had one year of follow-up on 56% to 66% of the
cohorts. The remainder will either have left the practice
before the end of the year or have been diagnosed within
Table 4: Number of changesa from initialb to stablec therapy by condition for initial treatments (drug(s) and dose) prescribed to ≥ 10 
patients
Initial treatment Patients Changes to stable therapy
Drug (dose) Treated 
(% all treated)
Followed >1 year 
(% treated)
Stable in 1 year 
(% followed)
Mean Median Range
Post-herpetic neuralgia
Amitriptyline hydrochloride (10 mg per day) 93 (6.6) 50 (53.8) 9 (18.0) 2.6 2 1–5
Amitriptyline hydrochloride (10 mg not specified) 65 (4.6) 36 (55.4) 4 (11.1) 4.8 5 2–8
Amitriptyline hydrochloride (25 mg per day) 64 (4.5) 39 (60.9) 10 (25.6) 2.6 3 1–5
Codeine phosphate (8 mg)+paracetamol (500 mg 
not specified)
34 (2.4) 21 (61.8) 9 (42.9) 4 2 1–12
Co-dydramol (not specified) Dihydrocodeine 
tartrate (10 mg)+paracetamol (500 mg)
30 (2.1) 20 (66.7) 7 (35.0) 5.6 4 1–18
Codeine phosphate (30 mg)+paracetamol (500 mg 
not specified)
24 (1.7) 15 (62.5) 5 (33.3) 5.4 5 1–9
Capsaicin (0.025% 4 times a day) 19 (1.3) 15 (78.9) 6 (40.0) 2.8 2 1–6
Carbamazepine (200 mg per day) 19 (1.3) 12 (63.2) 7 (58.3) 4 4 1–8
Paracetamol (500 mg not specified) 18 (1.3) 14 (77.8) 4 (28.6) 2.8 2 1–6
Co-proxamol (not specified) Dextropropoxyphene 
hydrochloride (32.5 mg)+paracetamol (325 mg)
17 (1.2) 11 (64.7) 2 (18.2) 5 5 3–7
Trigeminal neuralgia
Carbamazepine (200 mg per day) 103 (8.8) 67 (65.0) 9 (13.4) 3.7 3 1–10
Amitriptyline hydrochloride (10 mg per day) 53 (4.6) 35 (66.0) 6 (17.1) 2 2 1–4
Amitriptyline hydrochloride (10 mg not specified) 43 (3.7) 33 (76.7) 3 (9.1) 1.3 1 1–2
Carbamazepine (300 mg per day) 35 (3.0) 22 (62.9) 8 (36.4) 2.1 2 1–4
Carbamazepine (100 mg not specified) 33 (2.8) 19 (57.6) 4 (21.1) 1.5 2 1–2
Amitriptyline hydrochloride (25 mg per day) 31 (2.7) 17 (54.8) 4 (23.5) 3.5 3 2–6
Carbamazepine (100 mg per day) 30 (2.6) 22 (73.3) 4 (18.2) 2.5 2 1–5
Carbamazepine (400 mg per day) 29 (2.5) 23 (79.3) 5 (21.7) 4.8 2 1–16
Gabapentin (300 mg per day) 21 (1.8) 14 (66.7) 5 (35.7) 2.8 3 1–4
Codeine phosphate (8 mg)+paracetamol (500 mg 
not specified)
20 (1.7) 12 (60.0) 3 (25.0) 5.7 6 5–6
Codeine phosphate (30 mg)+paracetamol (500 mg 
not specified)
19 (1.6) 13 (68.4) 4 (30.8) 2 1 1–5
Co-proxamol (not specified) Dextropropoxyphene 
hydrochloride (32.5 mg)+paracetamol (325 mg)
14 (1.2) 11 (78.6) 1 (9.1) 1 1 1-1
Painful diabetic neuropathy
Amitriptyline hydrochloride (10 mg per day) 72 (7.8) 35 (48.6) 4 (11.4) 1.5 2 1–2
Amitriptyline hydrochloride (25 mg per day) 41 (4.4) 25 (61.0) 7 (28.0) 3 2 1–11
Amitriptyline hydrochloride (10 mg not specified) 35 (3.8) 21 (60.0) 2 (9.5) 1 1 1-1
Gabapentin (900 mg per day) 30 (3.3) 15 (50.0) 5 (33.3) 5.2 4 2–12
Co-dydramol (not specified) Dihydrocodeine 
tartrate (10 mg)+paracetamol (500 mg)
21 (2.3) 15 (71.4) 4 (26.7) 2.8 1 1–8
Paracetamol (500 mg not specified) 20 (2.2) 11 (55.0) 1 (9.1) 1 1 1-1
Codeine phosphate (8 mg)+paracetamol (500 mg 
not specified)
18 (2.0) 13 (72.2) 1 (7.7) 2 2 2-2
aTreatment changes comprised each switch, discontinuation, new treatment or addition of a concomitant treatment, but not a change in dose. 
bStarted within 28 days of the first record of the disease. cMore than two prescriptions for the same treatment with less than 56 days between each 
one.BMC Family Practice 2008, 9:26 http://www.biomedcentral.com/1471-2296/9/26
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a year of either the last data collection or the end of the
study period. Fewer patients with post-herpetic neuralgia
and trigeminal neuralgia were followed to stable regimen
than those with phantom limb pain and painful diabetic
neuropathy. This difference may be partly the result of our
definition rather than an indication that patients with
post-herpetic neuralgia and trigeminal neuralgia have
more difficulty achieving effective pain relief. Stable ther-
apy was defined as more than two prescriptions for the
same treatment. As post-herpetic neuralgia may wane
while trigeminal neuralgia can be intermittent these
patients may not require a third consecutive prescription.
Results of the January 1992 to April 2002 analysis sug-
gested that, for the most commonly prescribed treat-
ments, changes to a treatment regimen appeared to be less
frequent when initial therapy was with frequently used
antidepressants or antiepileptics rather than compound
analgesics. Our ability to explore this further in more
recent cohorts is limited given that conventional analge-
sics were prescribed less frequently and severity of pain or
underlying disease cannot be accounted for in the dataset.
However, the mean change in therapy within cohorts was
slightly greater in this study (2–3 changes compared to 1–
2 changes) despite a larger proportion receiving antiepi-
leptics and antidepressants. Conversely, the mean dura-
tion of the initial treatment increased, 50 to 90 days
compared to 47 to 76 days previously, as did the number
of initial prescriptions with more than one item (28% to
43% compared to 7% to 19% previously) [8].
Conclusion
Incidence rates of phantom limb pain and post-herpetic
neuralgia as seen in UK general practice continue to
change, although the reasons for this are not clear. Treat-
ment patterns at the time of the first diagnosis have also
changed as the use of antidepressant and antiepileptics
has increased and is common across all conditions stud-
ied with most patients prescribed one item. Although this
is in line with directives, frequent changes to therapy
before a stable regimen is reached suggest that pain relief
with tolerability are difficult to achieve.
Abbreviations
THIN: The Health Information Network database; NHS:
National Health Service; GP: General Practitioner; UK:
United Kingdom.
Competing interests
Gillian Hall has received funding for research and pay-
ment for consultancy from a number of pharmaceutical
companies and charities and has no direct stock holding
in any pharmaceutical company. Dawn Carroll was an
employee of Pfizer Inc. Henry McQuay has received
research support, consultancy and lecture fees from phar-
maceutical companies, charities and government sources,
and has no direct stock holding in any pharmaceutical
company.
Authors' contributions
All authors formulated the research questions. GH partic-
ipated in the design of the study and was responsible for
the analysis and interpretation of the patient database and
drafting and finalising the paper. DC and HMcQ partici-
pated in the design of the study and commented on the
paper. All authors read and approved the final manu-
script.
Additional material
Acknowledgements
The study was funded by Pfizer UK, including funding of the authors time, 
comment on study design and the manuscript but with no direct involve-
ment in the collection, analysis, and interpretation of data and no restric-
tion on publication.
The authors would like to thank those at practices which contribute data 
to the THIN database and Steve Morant for his programming. Steve Morant 
was funded by Pfizer UK.
References
1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D: Survey of
chronic pain in Europe: prevalence, impact on daily life, and
treatment.  Eur J Pain 2006, 10:287-333.
2. Brown GR: Herpes zoster: correlation of age, sex, distribu-
tion, neuralgia, and associated disorders.  South Med J 1976,
69:576-578.
3. Boulton AJ, Knight G, Drury J, Ward JD: The prevalence of symp-
tomatic, diabetic neuropathy in an insulin-treated popula-
tion.  Diabetes Care 1985, 8:125-128.
4. Chan AW, MacFarlane IA, Bowsher D, Wells JC, Bessex C, Griffiths
K: Chronic pain in patients with diabetes mellitus: compari-
son with a non-diabetic population.  Pain Clinic 1990, 3:147-159.
5. O'Hare JA, Abuaisha F, Geoghegan M: Prevalence and forms of
neuropathic morbidity in 800 diabetics.  Ir J Med Sci 1994,
163:132-135.
6. Kooijman CM, Dijkstra PU, Geertzen JH, Elzinga A, van der Schans
CP: Phantom pain and phantom sensations in upper limb
amputees: an epidemiological study.  Pain 2000, 87:33-41.
7. Torrance N, Smith BH, Bennett MI, Lee AJ: The epidemiology of
chronic pain of predominantly neuropathic origin. Results
from a general population survey.  J Pain 2006, 7:281-289.
8. Hall GC, Carroll D, Parry D, McQuay HJ: Epidemiology and treat-
ment of neuropathic pain: The UK primary care perspective.
Pain 2006, 122:156-162.
9. MHRA:  Co-proxamol: outcome of the review of risks and
benefits.   [http://www.mhra.gov.uk/home/idcplg?IdcServ
ice=GET_FILE&dDocName=CON019462&RevisionSelection
Method=Latest].
Additional file 1
Read codes with terms used for identification of four neuropathic pain 
cohorts.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2296-9-26-S1.xls]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Family Practice 2008, 9:26 http://www.biomedcentral.com/1471-2296/9/26
Page 9 of 9
(page number not for citation purposes)
10. Department of Health: PRODIGY Guidance - Shingles and post-
herpetic neuralgia.   [http://cks.library.nhs.uk/
shingles_postherpetic_pain/].
11. NHS Centre for Coding and Classification: The READ Codes Ver-
sion 3.  London, Stationary Office; 1996. 
12. Office for National Statistics, General Register Office for Scotland,
Northern Ireland Statistics and Research Agency.: Mid-2005 Popu-
lation Estimates: United Kingdom; estimated resident popu-
lation by single year of age and sex.   [ h t t p : / /
www.statistics.gov.uk/statbase/Expodata/Spreadsheets/D9387.xls].
13. Joint Formulary Committee: British National Formulary 51.
[http://www.bnf.org/bnf/].
14. National Statistics: Census 2001.   [http://www.statistics.gov.uk/
census2001/pyramids/pages/UK.asp].
15. Cockerell OC, Goodridge DM, Brodie D, Sander JW, Shorvon SD:
Neurological disease in a defined population: the results of a
pilot study in two general practices.  Neuroepidemiology 1996,
15:73-82.
16. Hope-Simpson RE: Postherpetic neuralgia.  J R Coll Gen Pract 1975,
25:571-575.
17. Crooks RJ, Jones DA, Fiddian AP: Zoster-associated chronic pain:
an overview of clinical trials with acyclovir.  Scand J Infect Dis
Suppl 1991, 80:62-68.
18. Opstelten W, van Essen GA, Moons KG, van Wijck AJ, Schellevis FG,
Kalkman CJ, Verheij TJ: Do herpes zoster patients receive anti-
virals? A Dutch national survey in general practice.  Fam Pract
2005, 22:523-528.
19. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA: Preva-
lence of postherpetic neuralgia after a first episode of herpes
zoster: prospective study with long term follow up.  BMJ 2000,
321:794-796.
20. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD: The inci-
dence and lifetime prevalence of neurological disorders in a
prospective community-based study in the UK.  Brain 2000,
123 ( Pt 4):665-676.
21. Brewis M, Poskanzer DC, Rolland C, Miller H: Neurological dis-
ease in an English city.  Acta Neurol Scand 1966, 42:Suppl 24:1-89.
22. Katusic S, Beard CM, Bergstralh E, Kurland LT: Incidence and clin-
ical features of trigeminal neuralgia, Rochester, Minnesota,
1945-1984.  Ann Neurol 1990, 27:89-95.
23. NHS Health and Social Care Information Centre: Hospital Episode
Statistics 2004/2005.   [http://www.hesonline.nhs.uk].
24. Department of Health: PRODIGY Guidance - Managing neuro-
pathic pain.   [http://cks.library.nhs.uk/palliative_care_pain/manage
ment/detailed_answe  rs/
which_types_of_pain_may_need_a_specific_approach/
how_should_i_manage_n  europathic_pain#-185543].
25. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA: A
systematic review of antidepressants in neuropathic pain.
Pain 1996, 68:217-227.
26. Merrison AF, Fuller G: Treatment options for trigeminal neu-
ralgia.  BMJ 2003, 327:1360-1361.
27. Department of Health: PRODIGY Guidance - Trigeminal neu-
ralgia.   [http://cks.library.nhs.uk/trigeminal_neuralgia].
28. Collins SL, Moore RA, McQuay HJ, Wiffen P: Antidepressants and
anticonvulsants for diabetic neuropathy and postherpetic
neuralgia: a quantitative systematic review.  J Pain Symptom
Manage 2000, 20:449-458.
29. Backonja MM, Serra J: Pharmacologic management part 1: bet-
ter-studied neuropathic pain diseases.  Pain Med 2004, 5 Suppl
1:S28-47.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2296/9/26/prepub